Therapy of human papillomavirus-related disease

Peter L. Stern, Sjoerd H. van der Burg, Ian N. Hampson, Thomas R. Broker, Alison Fiander, Charles J. Lacey, Henry C. Kitchener, Mark H. Einstein

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

This chapter reviews the current treatment of chronic and neoplastic human papillomavirus (HPV)-associated conditions and the development of novel therapeutic approaches. Surgical excision of HPVassociated lower genital tract neoplasia is very successful but largely depends on secondary prevention programmes for identification of disease. Only high-risk HPV-driven chronic, pre-neoplastic lesions and some very early cancers cannot be successfully treated by surgical procedures alone. Chemoradiation therapy of cervical cancer contributes to the 66-79% cervical cancer survival at 5 years. Outlook for those patients with persistent or recurrent cervical cancer following treatment is very poor. Topical agents such as imiquimod (immune response modifier), cidofovir (inhibition of viral replication; induction apoptosis) or photodynamic therapy (direct damage of tumour and augmentation of anti-tumour immunity) have all shown some useful efficacy (~50-60%) in treatment of high grade vulvar intraepithelial neoplasia (VIN). Provider administered treatments of genital warts include cryotherapy, trichloracetic acid, or surgical removal which has the highest primary clearance rate. Patient applied therapies include podophyllotoxin and imiquimod. Recurrence after "successful" treatment is 30-40%. Further improvements could derive from a rational combination of current therapy with new drugs targeting molecular pathways mediated by HPV in cancer. Small molecule inhibitors targeting the DNA binding activities of HPV E1/E2 or the antiapoptotic consequences of E6/E7 oncogenes are in preclinical development. Proteasome and histone deacetylase inhibitors, which can enhance apoptosis in HPV positive tumour cells, are being tested in early clinical trials. Chronic high-risk HPV infection/neoplasia is characterised by systemic and/or local immune suppressive regulatory or escape factors. Recently two E6/E7 vaccines have shown some clinical efficacy in high grade VIN patients and this correlated with strong and broad systemic HPV-specific T cell response and modulation of key local immune factors. Treatments that can shift the balance of immune effectors locally in combination with vaccination are now being tested.

Original languageEnglish (US)
JournalVaccine
Volume30
Issue numberSUPPL.5
DOIs
StatePublished - 2012

Fingerprint

Papillomaviridae
therapeutics
neoplasms
uterine cervical neoplasms
Neoplasms
imiquimod
Uterine Cervical Neoplasms
Therapeutics
genitalia
apoptosis
cryosurgery
warts
histone deacetylase
modifiers (genes)
excision
new drugs
oncogenes
Podophyllotoxin
Apoptosis
proteasome endopeptidase complex

Keywords

  • HPV drug targets
  • HPV-related disease therapy
  • Therapeutic HPV vaccines

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Stern, P. L., van der Burg, S. H., Hampson, I. N., Broker, T. R., Fiander, A., Lacey, C. J., ... Einstein, M. H. (2012). Therapy of human papillomavirus-related disease. Vaccine, 30(SUPPL.5). https://doi.org/10.1016/j.vaccine.2012.05.091

Therapy of human papillomavirus-related disease. / Stern, Peter L.; van der Burg, Sjoerd H.; Hampson, Ian N.; Broker, Thomas R.; Fiander, Alison; Lacey, Charles J.; Kitchener, Henry C.; Einstein, Mark H.

In: Vaccine, Vol. 30, No. SUPPL.5, 2012.

Research output: Contribution to journalArticle

Stern, PL, van der Burg, SH, Hampson, IN, Broker, TR, Fiander, A, Lacey, CJ, Kitchener, HC & Einstein, MH 2012, 'Therapy of human papillomavirus-related disease', Vaccine, vol. 30, no. SUPPL.5. https://doi.org/10.1016/j.vaccine.2012.05.091
Stern PL, van der Burg SH, Hampson IN, Broker TR, Fiander A, Lacey CJ et al. Therapy of human papillomavirus-related disease. Vaccine. 2012;30(SUPPL.5). https://doi.org/10.1016/j.vaccine.2012.05.091
Stern, Peter L. ; van der Burg, Sjoerd H. ; Hampson, Ian N. ; Broker, Thomas R. ; Fiander, Alison ; Lacey, Charles J. ; Kitchener, Henry C. ; Einstein, Mark H. / Therapy of human papillomavirus-related disease. In: Vaccine. 2012 ; Vol. 30, No. SUPPL.5.
@article{ecc7213b475f4f35bc8f392ed8a825f9,
title = "Therapy of human papillomavirus-related disease",
abstract = "This chapter reviews the current treatment of chronic and neoplastic human papillomavirus (HPV)-associated conditions and the development of novel therapeutic approaches. Surgical excision of HPVassociated lower genital tract neoplasia is very successful but largely depends on secondary prevention programmes for identification of disease. Only high-risk HPV-driven chronic, pre-neoplastic lesions and some very early cancers cannot be successfully treated by surgical procedures alone. Chemoradiation therapy of cervical cancer contributes to the 66-79{\%} cervical cancer survival at 5 years. Outlook for those patients with persistent or recurrent cervical cancer following treatment is very poor. Topical agents such as imiquimod (immune response modifier), cidofovir (inhibition of viral replication; induction apoptosis) or photodynamic therapy (direct damage of tumour and augmentation of anti-tumour immunity) have all shown some useful efficacy (~50-60{\%}) in treatment of high grade vulvar intraepithelial neoplasia (VIN). Provider administered treatments of genital warts include cryotherapy, trichloracetic acid, or surgical removal which has the highest primary clearance rate. Patient applied therapies include podophyllotoxin and imiquimod. Recurrence after {"}successful{"} treatment is 30-40{\%}. Further improvements could derive from a rational combination of current therapy with new drugs targeting molecular pathways mediated by HPV in cancer. Small molecule inhibitors targeting the DNA binding activities of HPV E1/E2 or the antiapoptotic consequences of E6/E7 oncogenes are in preclinical development. Proteasome and histone deacetylase inhibitors, which can enhance apoptosis in HPV positive tumour cells, are being tested in early clinical trials. Chronic high-risk HPV infection/neoplasia is characterised by systemic and/or local immune suppressive regulatory or escape factors. Recently two E6/E7 vaccines have shown some clinical efficacy in high grade VIN patients and this correlated with strong and broad systemic HPV-specific T cell response and modulation of key local immune factors. Treatments that can shift the balance of immune effectors locally in combination with vaccination are now being tested.",
keywords = "HPV drug targets, HPV-related disease therapy, Therapeutic HPV vaccines",
author = "Stern, {Peter L.} and {van der Burg}, {Sjoerd H.} and Hampson, {Ian N.} and Broker, {Thomas R.} and Alison Fiander and Lacey, {Charles J.} and Kitchener, {Henry C.} and Einstein, {Mark H.}",
year = "2012",
doi = "10.1016/j.vaccine.2012.05.091",
language = "English (US)",
volume = "30",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "SUPPL.5",

}

TY - JOUR

T1 - Therapy of human papillomavirus-related disease

AU - Stern, Peter L.

AU - van der Burg, Sjoerd H.

AU - Hampson, Ian N.

AU - Broker, Thomas R.

AU - Fiander, Alison

AU - Lacey, Charles J.

AU - Kitchener, Henry C.

AU - Einstein, Mark H.

PY - 2012

Y1 - 2012

N2 - This chapter reviews the current treatment of chronic and neoplastic human papillomavirus (HPV)-associated conditions and the development of novel therapeutic approaches. Surgical excision of HPVassociated lower genital tract neoplasia is very successful but largely depends on secondary prevention programmes for identification of disease. Only high-risk HPV-driven chronic, pre-neoplastic lesions and some very early cancers cannot be successfully treated by surgical procedures alone. Chemoradiation therapy of cervical cancer contributes to the 66-79% cervical cancer survival at 5 years. Outlook for those patients with persistent or recurrent cervical cancer following treatment is very poor. Topical agents such as imiquimod (immune response modifier), cidofovir (inhibition of viral replication; induction apoptosis) or photodynamic therapy (direct damage of tumour and augmentation of anti-tumour immunity) have all shown some useful efficacy (~50-60%) in treatment of high grade vulvar intraepithelial neoplasia (VIN). Provider administered treatments of genital warts include cryotherapy, trichloracetic acid, or surgical removal which has the highest primary clearance rate. Patient applied therapies include podophyllotoxin and imiquimod. Recurrence after "successful" treatment is 30-40%. Further improvements could derive from a rational combination of current therapy with new drugs targeting molecular pathways mediated by HPV in cancer. Small molecule inhibitors targeting the DNA binding activities of HPV E1/E2 or the antiapoptotic consequences of E6/E7 oncogenes are in preclinical development. Proteasome and histone deacetylase inhibitors, which can enhance apoptosis in HPV positive tumour cells, are being tested in early clinical trials. Chronic high-risk HPV infection/neoplasia is characterised by systemic and/or local immune suppressive regulatory or escape factors. Recently two E6/E7 vaccines have shown some clinical efficacy in high grade VIN patients and this correlated with strong and broad systemic HPV-specific T cell response and modulation of key local immune factors. Treatments that can shift the balance of immune effectors locally in combination with vaccination are now being tested.

AB - This chapter reviews the current treatment of chronic and neoplastic human papillomavirus (HPV)-associated conditions and the development of novel therapeutic approaches. Surgical excision of HPVassociated lower genital tract neoplasia is very successful but largely depends on secondary prevention programmes for identification of disease. Only high-risk HPV-driven chronic, pre-neoplastic lesions and some very early cancers cannot be successfully treated by surgical procedures alone. Chemoradiation therapy of cervical cancer contributes to the 66-79% cervical cancer survival at 5 years. Outlook for those patients with persistent or recurrent cervical cancer following treatment is very poor. Topical agents such as imiquimod (immune response modifier), cidofovir (inhibition of viral replication; induction apoptosis) or photodynamic therapy (direct damage of tumour and augmentation of anti-tumour immunity) have all shown some useful efficacy (~50-60%) in treatment of high grade vulvar intraepithelial neoplasia (VIN). Provider administered treatments of genital warts include cryotherapy, trichloracetic acid, or surgical removal which has the highest primary clearance rate. Patient applied therapies include podophyllotoxin and imiquimod. Recurrence after "successful" treatment is 30-40%. Further improvements could derive from a rational combination of current therapy with new drugs targeting molecular pathways mediated by HPV in cancer. Small molecule inhibitors targeting the DNA binding activities of HPV E1/E2 or the antiapoptotic consequences of E6/E7 oncogenes are in preclinical development. Proteasome and histone deacetylase inhibitors, which can enhance apoptosis in HPV positive tumour cells, are being tested in early clinical trials. Chronic high-risk HPV infection/neoplasia is characterised by systemic and/or local immune suppressive regulatory or escape factors. Recently two E6/E7 vaccines have shown some clinical efficacy in high grade VIN patients and this correlated with strong and broad systemic HPV-specific T cell response and modulation of key local immune factors. Treatments that can shift the balance of immune effectors locally in combination with vaccination are now being tested.

KW - HPV drug targets

KW - HPV-related disease therapy

KW - Therapeutic HPV vaccines

UR - http://www.scopus.com/inward/record.url?scp=84875173644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875173644&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.05.091

DO - 10.1016/j.vaccine.2012.05.091

M3 - Article

VL - 30

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - SUPPL.5

ER -